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Abstract
The aim. Assessment of the dynamics of prescribing drugs to patients with liver cirrhosis (LC, K 74), in terms of real clinical 
practice by methods of clinical and economic analysis.
Materials and methods. 355 medical cards of inpatients with cirrhosis of the liver, which were divided into 4 groups de-
pending on the period of stay of patients in the hospital. Methods: compatible retrospective ABC-frequency analysis, which ranked 
drugs consumed by patients in real clinical practice, according to the frequency of appointment using ABC-segmentation according 
to the Pareto principle (A – 80 % of drugs appointments: B – 15 %: C – 5 %); VEN-analysis, which divides the consumed drugs on 
a formal basis depending on the presence/absence of a particular drug in the regulations: vital (Vital or V), necessary (Essential or E) 
and secondary (Non-essential or N). 
Results. Cirrhosis of the liver in recent years has been on the 10th - 11th place among the causes of death in the world. The 
analysis of prescribed drugs to patients with LC in real clinical practice in Ivano-Frankivsk region of Ukraine revealed that over the 
years doctors prescribed fewer drugs on average per patient (11.4 drugs → 8.8 drugs), which can be considered a positive fact. Among 
the prescribed drugs, drugs of group A – «Drugs that affect the digestive system and metabolism» prevailed, the share of which in-
creased and was the highest in 2019 – 2020 (2007–2009 – 44.6 %; 2012–2013 – 46.6 %; 2015–2016 – 48.1 %; 2019–2020 – 48.55 %); 
the share of dietary supplements also increased from 1.65 % to 6.52 %. 
Conclusions. Combined ABC-frequency and VEN-analyzes showed that the leaders in the years of hospital stay were the 
following drugs: Sodium chloride, Ademetionine, Pantoprazole, Spironolactone, Thioctic acid, Ornithine, Asparaginate K-Mg, To-
rasemide, Furosemide. However, the vital class V included only 9–11 % of drugs from the whole set of prescribed drugs, which 
requires systemic correction in accordance with European recommendations. 
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1. Introduction
Chronic liver disease occurs worldwide regardless of age, gender, region or race. Liver cir-
rhosis (LC) is the final stage of chronic liver disease, characterized by fibrosis and transformation 
of the normal structure of the liver with the formation of regenerative nodules and can have a variety 
of clinical manifestations and complications [1].
In 2017, LC caused the deaths of more than 1.32 million people [1.27–1.45], of which 
440.000 [416.000–518.000] women and 883.000 [838.000–967.000] men worldwide, compared 
with 899.000 [829.000 –948.000] deaths in 1990. Mortality from LC was 2.4 % [2.3–2.6] of the 
total number of deaths in the world in 2017, compared with 1.9 % [1.8–2.0] in 1990. At the national 
level, the standardized mortality rate from LC was the lowest in Singapore in 2017 (3.7 [3.3–4.0] 
per 100,000) and the highest in Egypt since 1990 (103.3 [64.4–133.4] per 100.000) [2]. According 
to the WHO, the standardized mortality rate due to LC per 100.000 population among women and 
men in 2016 in different countries was: the highest in Egypt – 121.6 and 200.4; the lowest in Fiji – 
0.8 and 1.6, respectively [3]. According to the latest WHO data published in 2018, mortality from 
liver disease in the world reached 1.247.237 and ranks 11th in the world ranking [4].
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As LC remains one of the leading causes of death worldwide, clinical and economic evalua-
tion of the pharmacotherapy consumed by patients with LC is relevant to optimize the provision of 
effective medical and pharmaceutical care.
The aim. Assessment of the dynamics of prescribed drugs to patients with liver cirrho-
sis (LC, K 74), in terms of real clinical practice by methods of clinical and economic analysis. 
2. Materials and methods
The sample for the study consisted of 355 medical cards form No. 003/o inpatients with 
LC (K 74), which were obtained by random selection from the archives of gastroenterological departments 
of Municipal Non-Commercial Enterprises «Regional Clinical Hospital of Ivano-Frankivsk Regional 
Council» and «Ivano-Frankivsk Central City Clinical Hospital». These medical records were divided 
into 4 groups depending on the period of stay of patients in the hospital. Thus, the first group consisted of 
56 medical cards of patients for 2007–2009, the second – 189 cards for 2012–2013, the third – 55 cards for 
2015–2016 and the fourth – 55 cards for 2019–2020. Permits of chief physicians of each health care institution 
were obtained to work with archival materials while maintaining the secrecy of personal data of patients.
The following methods were used for the study: frequency method of clinical and economic 
research, which consisted of ranking the drugs consumed by frequency of use – in the whole set of 
purposes and among the names of drugs by international non-proprietary names (INN); compa tible 
ABC-frequency method, which consisted in the distribution of prescribed drugs according to the Pare-
to principle (group A – 80 % of drug prescriptions, group B – 15 %, and group C – 5 %); VEN-analysis, 
which distributed the consumed drugs on a formal basis depending on the presence/absence of certain 
drugs in regulations (class V – required drugs (draft Unified Clinical Protocol of primary, secon-
dary (specialized) tertiary (highly specialized) medical care «Liver cirrhosis and its complications», 
2016, based on evidence-based medicine), class E – important drugs (Clinical protocol for medical 
care for patients with cirrhosis of the liver, approved by the order of the Ministry of Health of Ukraine 
No. 271 from 13.06.2005), group N – unimportant drugs, other drugs not included in classes V and E).
3. Research results
A retrospective clinical and economic study of prescriptions revealed that 641 patients with 
LC were prescribed 641 drugs by trade name, which averaged 11.4 drugs per patient; II group – 
1 989 in total and 10.5 drugs in average; III group – 624 in total and 11.3 drugs in average; group 
IV – 484 in total and 8.8 drugs in average, respectively. A total of 121 names of drugs by INN for 
the first study group, 146 drugs by INN – for the second study group, 107 drugs by INN – for the 
third group and 88 drugs by INN – for the fourth group groups.
This analysis also revealed that patients of the first group were prescribed drugs belonging to the 
9 ATC classification groups and 2 units of biologically active additives (dietary supplements) (Fig. 1, a), 
persons of the second group – drugs who belonged to the 11 ATC classification groups and 8 units 
of dietary supplements (Fig. 1, b), patients of the III group – drugs belonging to the 10 ATC classi-
fication groups and 6 units of dietary supplements (Fig. 1, c), and patients of the IV group – drugs 
belonging to the 9 ATC classification groups and 9 units of dietary supplements (DS) (Fig. 1, d).
The data graphically shown in Fig. 1, illustrate that the leader among the ATC classification 
groups during all years was group A – ЄDrugs that affect the digestive system and metabolism, 
namely: 44.6 %, 46.6 %, 48.1 % and 48.55 % respectively. The second position is occupied by 
group C – «Drugs for the treatment of diseases of the cardiovascular system» for the I and II groups 
of 15.7 % and 14.08 %, and for the III and IV – group B – «Means affecting the blood system and 
hematopoiesis» 11.4 % and 13.4 %, respectively. The third place is also occupied by groups B and C, 
but on the contrary: for the I and II groups – group B – 14.9 % and 10.7 %, respectively, and for the 
III and IV – group C – 10.13 % and 10.87 %, respectively.
Combined ABC-frequency analysis showed the following: in the first study group of medi cal 
records, group A, which provided 80 % of drugs prescriptions, amounted to 38 drugs per INN, which 
was 31 %, group B – 51 drugs per INN (42 %), group C – 32 drugs for INN (27 %); in the second – 
30 drugs, 44 drugs, 72 drugs by INN (21 %, 30 %, 49 %); in the third – 27 drugs, 50 drugs, 31 drugs (25 %, 
46 %, 29 %); in the IV – 25 drugs, 38 drugs, 25 drugs (29 %, 43 %, 28 %), respectively (Fig. 2).
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Fig. 1. The level of consumption of drugs by ATC classification groups according  
to the years of stay of patients in the hospital: a – 2007–2009; b – 2012–2013;  
c – 2015–2016; d – 2019–2020
Fig. 2. Distribution of drugs by joint ABC-frequency analysis for the I-th (a), II-th (b),  
III-th (c) and IV-th (d) study groups in the dynamics of the years of appointment:  
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The leaders in groups A by years of hospital stay were the following drugs: Sodium chlo-
ride, Ademetionine, Pantoprazole, Spironolactone, Thioctic acid, Ornithine, Asparaginate K-Mg, 
Phhospholipids, Torasemide, Furosemide.
The next stage of the study was a VEN-analysis of the pharmacotherapy consumed by pa-
tients in the relevant periods according to the INN. The distribution of drugs by classes of rationality 
is presented in Table 1. 
Table 1
The principle of distribution of drugs prescribed to patients with LC in real clinical practice, according to 
the classes of rationality
V class E class N class
Diuretics (Spironolactone, Furosemide) Other diuretics
All other drugs that 
have been used to treat 
the study groups of pa-
tients with LC
Antimicrobial drugs (Amoxicillin + Сlavulonic аcid, Hemiflo-
xacin, Levofloxacin, Metronidazole, Moxifloxacin, Norfloxacin, 





Antiviral drugs (Pegylated Interferon alpha, Ribavirin, Simepre-






Preparations of hormones of the posterior pituitary gland: (Terli-
pressin)
Preparations of calcium and fat-so-
luble vitamins A, E, D, K.
Drugs of different pharmacotherapeutic groups for the treatment 
of LC (L-Ornithine-L-Aspartate, Lactulose, Rifaximin, Silymarin)
Drugs for infusion therapy
Other amino acid preparations
Beta-blockers (Carvedilol, Propranolol) Other beta-blockers
Blood substitutes and protein fractions of blood plasma (Albumin) Prebiotics
In Fig. 3 graphically shows the percentage of drugs in each class V, E and N for the respec-
tive periods. 
Fig. 3. Distribution of drugs by VEN-analysis for the 1st (a), II (b), III (c) and IV (d) groups  
of the studied groups in the dynamics of the years of appointment: a – 2007–2009; b – 2012–2013; 
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Table 2 shows the TOP-20 drugs by INN by frequency of use for the treatment of patients 
with LC for the study groups. The absolute leader in prescriptions in each group of studied medi-
cal records of patients with LC was a universal solvent – isotonic solution of Sodium chloride, 
which was used as a basis for infusion therapy (Ademetionine, Ornithine, Arginine). The top three 
drugs – Ademetionine, Pantoprazole, Spironolactone – remained unchanged during the last 2 study 
periods – in 2019–2020 and 2015–2016.
And according to VEN-segmentation in TOP-20 drugs during the years of research from the 
proposed class V there were only 4 drugs by INN, namely: Spironolactone, which took 1st place 
in the ranking of appointments in 2015–2016, 2nd – during 2012–2013 and 2007–2009, 3rd – 
2019–2020; Ornithine, which was 5th in the ranking in 2015–2016, 6th in 2019–2020, 12th in 2012–2013 
and was absent among prescribed drugs in 2007–2009; Furosemide, which was more often pre-
scribed in 2007–2009 (5th in the ranking), in 2012–2013 and in 2015–2016 it was 9th, and in 
2019–2020 – 12th; Albumin, which rose in the rankings in recent years – was 15th in 2015–2016 
and 18th in 2019–2020, in 2012–2013 ranked 33rd, and in 2007–2009 – only the 52nd. 
From class E in the TOP–20 drugs according to INN there were 8 drugs, from class N – 
8 drugs, which is explained by the presence of concomitant diseases (chronic pancreatitis, gastric 
ulcer) in patients with LC, for the treatment of which drugs were also prescribed.
Comparison of the results of real clinical practice with the Ukrainian protocol showed the 
lack of an effective formulaic approach to prescribing drugs to patients in Ukraine, as the list of 
actually consumed drugs is wider than legally recommended.
Table 2


























































Ademetioninе E 1 90.91 10.33 2 69.09 6.09 4 51.32 4.88 16 17.86 1.56
Pantoprazolе N 2 45.45 5.17 3 63.64 5.61 8 33.33 3.17 34 8.93 0.78
Spironolactone V 3 43.64 4.96 1 76.36 6.73 2 61.38 5.83 2 69.64 6.08
Тhioctic acid Е 4 38.18 4.34 8 40.00 3.53 1 71.43 6.79 1 76.79 6.71
Ursodeoxycholic acid E 5 38.18 4.34 14 20.00 1.76 13 22.22 2.11 14 21.43 1.87
Оrnithine V 6 36.36 4.13 5 58.18 5.13 12 25.93 2.46 – – –
Asparaginat K-Mg N 7 34.55 3.93 4 61.82 5.45 6 46.56 4.42 4 46.43 4.06
Pancreatin E 8 30.91 3.51 11 32.73 2.88 3 51.85 4.93 6 41.07 3.59
Torasemide E 9 29.09 3.31 7 43.64 3.85 22 13.23 1.26 17 17.86 1.56
Еsomeprazole N 10 27.27 3.10 – – – 14 17.99 1.71 – – –
Heparhizine N 11 20.0 2.27 – – – – – – – – –
Furosemide V 12 18.18 2.07 9 40.00 3.53 9 32.80 3.12 5 44.64 3.90
Аrginine E 13 18.18 2.07 13 20.00 1.76 5 47.09 4.47 3 53.57 4.68
Мenadione E 14 18.18 2.07 12 27.27 2.40 15 17.99 1.71 22 14.29 1.25
Аluminum hydro- 
xide + magnesium 
hydroxide 
N 15 14.55 1.65 18 14.55 1.28 11 28.04 2.66 12 25.00 2.18
Thiotriazoline E 16 14.55 1.65 19 12.73 1.12 19 15.34 1.46 9 30.36 2.65
Mebeverine N 17 14.55 1.65 60 1.82 0.16 26 10.05 0.96 23 12.50 1.09
Albumin V 18 12.73 1.45 15 20.00 1.76 33 6.88 0.65 52 3.57 0.31
Methylprednisolone N 19 12.73 1.45 30 5.45 0.48 47 3.17 0.3 – – –
Bionorm N 20 12.73 4.45 40 3.64 0.32 77 1.06 0.10 – – –
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4. Discussion
Tao Guo, Lei Chang, Yusha Xiao, Quanyan Liu [5] support the efficacy and safety of Ade-
metionine for the treatment of chronic liver disease, but in cholestasis or viral hepatitis it is, in 
their opinion, less effective. This drug was the leader in real clinical practice appointments in the 
Ivano-Frankivsk region of Ukraine in 2019–2020 compared to 2007–2008, when it occupied 16 
of the top 20 positions (Table 2). H. Lewis, J. G. Stine [6] claim that proton pump inhibitors are 
quite often prescribed to patients with LC (approximately 40 % of 400 patients). However, they are 
associated with a higher risk of developing spontaneous bacterial peritonitis with cirrhotic drugs 
and should be used with caution or avoided altogether. At the same time, in recent years in Ukraine 
drugs of this group (Pantoprazole) entered the top three drugs, although in 2007–2009 it occupied 
34 rating positions (Table 2). Bernardi M., Moore K. P., Wong F., Gines P., Santos J., Planas R., 
Pardo A., Durandez R., Cabre E. and others [7–9] claim that aldosterone antagonists (Spironolac-
tone) are the basis for the treatment of ascites in the early stages and are most often recommended, 
and the combination with Furosemide is most appropriate for patients with recurrent ascites; how-
ever, Benmassaoud A., Freeman S.C., Roccarina D. and others suggest that such a combination of 
diuretics may double the development of other liver complications in cirrhosis [10]. Spironlactone 
is one of the leaders in drug prescriptions in Ukraine (Table 2). Albumin is more effective than 
other plasma substitutes (dextran-70, polygelin) for the prevention of circulatory dysfunction af-
ter paracentesis [7–9], and in combination with Terlipressin used in the treatment of hepatorenal 
syndrome, drugs are recommended as standard therapy [11–12]. Mittal V. V., Sharma B. C., Shar-
ma P., Sarin S. K. recommend Lactulose as a first-line drug in the treatment of hepatic encepha-
lopathy [13–15], and Ndraha S., Hasan I., Goh E., Stokes C. S. and others believe that intravenous 
L-ornithine L-aspartate (LOLA) can be used as an alternative or adjunct in patients with ineffective 
basic therapy [16–18]. The first line of treatment for spontaneous bacterial peritonitis is antibiotics: 
third-generation cephalosporins (Cefotaxim, Ceftriaxon), alternatives include amoxicillin/clavu-
lanic acid (Amoxicillin+clavulanate) and fluoroquinolones (Ofloxacin, Norfloxacin) [19–21]. 
Study limitations. The study of approaches to prescribing pharmacotherapy to patients with 
LC in real clinical practice in Ukraine was limited to 2 health care facilities in Ivano-Frankivsk region. 
Prospects for further research. Carrying out a similar study based on medical card ap-
pointment sheets of inpatients with liver cirrhosis (K 74), which were observed in health care faci-
lities of other regions of Ukraine, as well as ABC/VEN-analysis of the cost of drugs consumed to 
assess the rational distribution of funds for pharmacotherapy. 
5. Conclusions
1. Mortality from liver diseases in the world remains high (in 2018 it ranked 11th among the 
causes of death)
2. Assessment of the dynamics of prescribing drugs to patients with LC in Ivano-Frankivsk 
region of Ukraine by retrospective ABC-frequency analysis revealed a positive trend in the number 
of prescriptions on average for one patient (11.4 drugs → 10.5 drugs → 11.3 drugs → 8.8 drugs in 
2007–2009 → 2012–2013 → 2015–2016 → 2019–2020, respectively), namely: over the years, doc-
tors have prescribed fewer drugs, which is a positive fact.
3. The leader among ATC-classification groups during all years of research was group A – 
«Drugs that affect the digestive system and metabolism», and their share has increased in recent 
years (44.6 % → 46.6 % → 48.1 % → 48.55 %), the share of dietary supplements also increased 
from 1.65 % to 6.52 %, which indicates a complex and lengthy procedure for registration of me-
dicines in Ukraine.
4. Compatible ABC–frequency analysis showed that the leaders in the years of hospital 
stay were drugs: Sodium chloride, Ademetionine, Pantoprazole, Spironolactone, Thioctic acid, 
Orni thine, Asparaginate K-Mg, Phhospholipids, Torasemide, Furosemide. Thus, in 2019–2020, the 
three leading drugs had the form – Ademetionine, Pantoprazole, Spironolactone; in 2015–2016 – 
Spironolactone, Ademetionine, Pantoprazole; in 2012–2013 – Thioctic acid, Spironolactone, Pan-
creatin; in 2007–2009 – Thioctic acid, Spironolactone, Arginine. Thus, in the leaders among drugs 
in each time period of the study remained only Spironolactone.
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5. VEN-analysis of real clinical practice in Ukraine showed that only 9–11 % of drugs were 
included in vital class V, 21–26 % of drugs in class E, 64–70 % of drugs in class N, which requires 
further correction.
6. The list of actually consumed drugs is wider than legally recommended, due to the pre-
sence of comorbidities, the severity of the patient’s LC (treatment in the last stages of the disease), 
the lack of a systematic approach to LC treatment based on evidence-based medicine, but there is 
a positive tendency to wider use of drugs with proven effectiveness in accordance with European 
recommendations.
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